Mitigating Toxicity and Monitoring QOL in Chronic Myeloid Leukemia

News
Video

Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.

Jorge E. Cortes, MD, spoke with CancerNetwork® atthe 2024 American Society of Clinical Oncology (ASCO) Annual Meeting about the potential implications for quality of life and toxicity as patients with chronic myeloid leukemia (CML) undergo treatment for their disease.

Cortes, director of the Georgia Cancer Center at August University, stated that many patients have adverse effects (AEs) during therapy, although these toxicities may improve or even resolve over time. Overall, he said that most patients would be able to pursue normal activities in their day-to-day lives as they receive treatment.

Some patients, however, may experience more severe instances of toxicity such as fatigue and diarrhea. Cortes highlighted that strategies including dietary interventions or switching anti-cancer therapies may help with mitigating these AEs, thereby minimizing negative impacts on patient quality of life.

Transcript:

For most patients, they are able to continue their normal lifestyle. There is no question that there’s going to be some changes. For one, there’s some [changes] based on testing and taking [a] pill. Many patients experience some adverse [effects]. Early on, we see more of these adverse [effects]. Over time, they tend to improve; many of them do, but not always. Many of them do improve; sometimes they disappear, and sometimes they at least get better. But for most patients, they’re able to continue their activities of daily living, work, play, and family.

But there are some patients who have more limitations. The fatigue [may be] more than expected where they have chronic diarrhea, or things like that. It’s always important to know that we can sometimes manage many of these things—not all of them—by managing the [adverse] effects. If [a patient] has diarrhea, is there a dietary intervention or medication [they] can take? Other [patients] can be [treated] by changing drugs; that is the alternative. In other instances when the [toxicity] is there and even changes, how can I optimize or at least minimize the impact in [their] quality of life?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Related Content